Compare

Palatin Technologies Inc vs Tonix Pharmaceuticals Holding Corp. vs Evommune, Inc. vs Pyxis Oncology, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearPalatin Technologies Inc
PTN
Tonix Pharmaceuticals Holding Corp.
TNXP
Evommune, Inc.
EVMN
Pyxis Oncology, Inc.
PYXS
Year ended2026-06-302025-12-312025-12-312025-12-31
Revenue$13.19M$13.11M$13.00M$13.86M
Revenue growth (YoY)n/a+29.8%+85.7%-14.2%
Gross marginn/a49.3% (computed)n/a82.8% (computed)
Operating margin-65.7%-959.1%-623.6%-609.2%
Net margin-63.5%-946.2%-529.8%-574.5%
Net income-$8.38M-$124.02M-$68.87M-$79.62M
EPS (Diluted)-$2.96-$14.57-$11.22-$1.28
Operating cash flow-$13.53M-$99.84M-$76.44M-$63.50M
Free cash flow-$13.58M-$103.21M-$76.68M-$63.51M
Cash & equivalents$7.49M$207.64M$44.06M$15.42M
Total assets$8.52M$277.17M$224.95M$91.52M
Total liabilities$1.84M$32.02M$19.38M$38.11M
Shareholders' equity$6.69M$245.15M$205.57M$53.41M
Return on year-end equity-125.3%-50.6%-33.5%-149.1%
Shares outstanding1.78M12.79M31.52M62.69M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearPalatin Technologies IncTonix Pharmaceuticals Holding Corp.Evommune, Inc.Pyxis Oncology, Inc.
Latest$13.19M
Ended 2026-06-30
$13.11M
Ended 2025-12-31
$13.00M
Ended 2025-12-31
$13.86M
Ended 2025-12-31
1 year earliern/a$10.09M
Ended 2024-12-31
$7.00M
Ended 2024-12-31
$16.15M
Ended 2024-12-31
2 years earliern/a$7.77M
Ended 2023-12-31
n/an/a
3 years earliern/an/an/an/a
4 years earliern/an/an/an/a